Drugs that do not dissolve well or are difficult for the body to absorb can be administered more efficiently with the use of fast dissolving tablets (FDTs), which are becoming more and more common. The goal of this work was to optimize and produce FDTs using sodium butyrate, which is known to be beneficial for several systemic illnesses and intestinal ailments. Creating this FDT was intended to increase the effectiveness of sodium butyrate when taken orally. To do this, a methodical approach was used to refine the formulation of Sodium Butyrate FDTs, utilizing several excipients such as β-cyclodextrin and crospovidone. These components were selected to enhance the solubility, rapid release, and general stability of sodium butyrate. The research included experimental techniques including factorial design, Response Surface Methodology (RSM) to carefully identify and optimize variables such as disintegrants, binders, and superdisintegrants. The effects of these variables on the tablet's physical and chemical characteristics, drug release profile, and disintegration time were examined. To compare the dissolved properties of the improved FDTs with ordinary tablets, in vitro dissolving tests were conducted. The improved sodium butyrate FDTs dissolved considerably more quickly, as demonstrated by the findings, assuring higher bioavailability and faster drug release.